Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 478-483

  Schwartz, Gary G ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CINACALCET; DOXERCALCIFEROL; PARATHYROID HORMONE RECEPTOR; PARICALCITOL; TAXANE DERIVATIVE;

ADVANCED CANCER; BONE METASTASIS; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;

BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS;

EID: 41549098603     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2747     Document Type: Review

References (70)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Galasko CSB. Skeletal metastases. London: Butterworth; 1986.
3. Logothetis CJ, Shin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8.
4. Vela I, Gregory L, Gardiner EM, Clements JA, Nicol DL. Bone and prostate cancer cell interactions in metastatic prostate cancer. BJU Int 2006;99:735-42.
5. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA. Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 1997;30:183-7.
6. 2+-sensing receptor from bovine parathyroid. Nature 1993;366:575-80.
7. Tfelt-Hansen J, Schwarz P, Brown EM, Chattopadhyay N. The calcium-sensing receptor in human disease. Front Biosci 2003;8:S377-90.
8. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999;56Suppl 73:S14-9.
9. Fukagawa M, Kurokawa K. Pathogenesis and medical treatment of secondary hyperparathyroidism. Semin Surg Oncol 1997;13:73-7.
10. Miles AMV, Markell KS, Sumrani N, Hong J, Friedman EA. Severe hyperparathyroidism associated with hungry bone syndrome in a renal transplant patient. J Am Soc Nephrol 1997;9:1626-32.
11. Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 1988;84:654-60.
12. Minisola S, Perugia G, Scarda A, et al. Biochemical picture accompanying sclerotic bone metastases of prostatic origin. Br J Urol 1987;60:443-6.
13. Ludwig GD. Hypocalcemia and hypophosphatemia accompanying osteoblastic osseous metastases: studies of calcium and phosphate metabolism and parathyroid function. Ann Intern Med 1962;56:676-7.
14. Charhon SA, Chapuy MC, Olmer M, Meunier PJ. et al. Parathyroid function and vitamin D status in patients with bone metastases of prostatic origin. Miner Electrolyte Metab 1985;11:117-22.
15. Smallridge RC, Wray HL, Schaaf M. Hypocalcemia with osteoblastic metastases in a patient with prostate carcinoma. A cause of secondary hyperparathyroidism. Am J Med 1981;71:184-8.
16. Rico H, Uson A, Hernandez ER, Prados P, Paramo P, Cabranes JA. Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study. Eur Urol 1990;17:35-9.
17. Kukreja SC, Shanmugam A, Lad TE. Hypocalcemia in patients with prostate cancer. Calcif Tissue Int 1988;43:340-5.
18. Szentirimai M, Constantinos C, Rainey JM, Loewenstein JE. Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. West J Med 1995;163:577-8.
19. Tandon PK, Rivvi AA. Hypocalcemia and parathyroid function in metastatic prostate cancer. Endocr Pract 2005;11:254-8.
20. Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999;45:1240-7.
21. Buchs N, Bonjour J-P, Rizzoli R. Renal tubular reabsoption of phosphate is positively related to the extent of bone metastatic load in patients with prostate cancer. J Clin Endocrinol Metab 1998;83:1535-41.
22. Murray RML, Grill V, Crinis N, Ho PWM, Davison J, Pitt P. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 2001;86:4133-8.
23. Mather HG. Hyperparathyroidism with normal serum calcium. Br Med J 1953;2:424-5.
24. Silverberg SJ. Natural history of primary hyperparathyroidism. Endocrinol Metab Clin North Am 2000;29:451-64.
25. Leder BZ, Smith MR, Fallon MA, Ling M-TL, Lee T, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2001;86:511-6.
26. Costa L, Demers LM, Gouiviea A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide I predicting bone metastases status. J Clin Oncol 2002;20:850-6.
27. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer (Hypothesis)? Anticancer Res 1990;11:1307-11.
28. Giovannucci E. Strengths and limitations of current epidemiologic studies: vitamin D as a modifier of colon and prostate risk. Nutr Rev 2007;65:577-9.
29. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Semin Dial 2005;18:276-89.
30. McCarty MF. Parathyroid hormone may be a cancer promoter - an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Med Hypotheses 2000;54:475-82.
31. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 2004;89-90:611-4.
32. Suva LJ. Editorial: PTH expression, not always where you think... J Clin Endocrinol Metab 2006;91:396-7.
33. Schnieder A, Kalikin LM, Mattos AC et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005;146:1727-36.
34. Deftos LJ, Barken I, Burton DW, Hoffman RM, Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophy Res Commun 2005;327:468-72.
35. Iwamura M, Abrahamsson PA, Foss KA, et al. PTHrP: a potential autocrine growth factor in human prostate cancer cell lines. Urology 1994;43:675-9.
36. Sepulveda VAT, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept 2002;105:109-20.
37. Asadi F, Kukreja S. Parathyroid hormone-related protein in prostate cancer. Crit Rev Eukaryot Gene Expr 2005;15:15-28.
38. Smith DC, Tucker A, Trump DL. Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. J Clin Oncol 1992;10:499-505.
39. Bryden AAG, Hoyland JA, Freemong AJ, Clarke NW, George NJR. Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer 2002;86:322-5.
40. Iddon J, Bundred NJ, Hoyland J, et al. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J Pathol 2000;91:170-4.
41. Pérez-Martínez FC, Alonso V, Sarasa JL, et al. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-κB ligand. J Clin Pathol 2007;60:290-4.
42. 2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 2005;11:8680-5.
43. Nilsson I-L, Wadsten C, Brandt L, Rastad J, Ekbom A. Mortality in sporadic primary hyperparathyroidism: nationwide cohort study of multiple parathyroid gland disease. Surgery 2004;136:981-7.
44. Thompson IM, Tangen CM, Tolcher A, Crawford ED, Eisenberger M, Moinpour CM. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 2001;93:219-25.
45. Godley PA, Schenck AP, Amamoo A, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 2003;95:1702-10.
46. Thatai LC, Banerjee M, Lai Z, Vaishampayan U. Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer. Urology 2004;64:738-43.
47. Fuleihan GE, Grundberg CM, Gleason R, et al. Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab 1994;79:1642-7.
48. Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, Butros R, Wedlund PJ, Fanti P. Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol 2002;57:51-5.
49. Brancaccio D, Bommer J, Coyne D. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism. Understanding the differences among therapies. Drugs 2007;67:1981-98.
50. Robinson DM, Scott LJ. Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs 2005;65:559-76.
51. Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Eng J Med 2004;350:1516-25.
52. Olson JA, Jr., Leight GS, Jr. Surgical management of secondary hyperparathyroidism. Adv Ren Replace Ther 2002;9:209-18.
53. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-9.
54. 3. Cancer Res 1992;2:515-20.
55. Krishnan AV, Moreno J, Nonn L, et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol 2007;103:694-702.
56. 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2007;27:1883-9.
57. Topar Sepulveda VA, Falzon M. Regulation of PTH-related protein gene expression by vitamin D in PC-3 prostate cancer cells. Mol Cell Endocr 2002;190:115-24.
58. Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res 2003;164:273-88.
59. Trump DL, Hersherger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004;89-90:519-26.
60. Schwartz GG. Vitamin D and intervention trials in prostate cancer: From theory to therapy. Ann Epidemiol. In press 2008.
61. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 2007;25:669-74.
62. Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006;12:6285-90s.
63. Wilt TJ, Ensrud EK. The if's, and's, or but's regarding bisphosphonates for prostate cancer. J Natl Cancer Inst 2007;10:744-5.
64. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer. J Natl Cancer Inst 2003;95:1300-11.
65. Patel K, Brahmbhatt V, Ramu V. Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases. Tenn Med 2005;98:83-5.
66. Topakian R, Stieglbauer K, Rotaru J, et al. Hypocalcemic choreoathetosis and tetany after bisphosphonate treatment. Mov Disord 2006;11:2026-7.
67. Schacht E, Dukas L, Richy F. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J Musculoskelet Neuronal Interact 2006;7:174-84.
68. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243-9S.
69. Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol 2006;49:429-40.
70. Dacal K. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 2006;54:85-90.